TGFB1 and neoplasm: The presented data demonstrated that nerve-cancer cross-talk not only activated TGFβ signaling and upregulated PD-L1 on tumor cells, but also decreased IFNγ and TNFα expression levels and reduced CD8+ T-cell activity in tumor parenchyma, resulting in impaired anticancer immunity and decreased immune checkpoint blockade responses.